论文部分内容阅读
作者采用DNA和胞浆免疫球蛋白(CytIg)作为细胞克隆标记来确定骨髓和外周血中微小残留骨髓瘤细胞。结果:1、使用多发性骨髓瘤细胞系人工混合物:骨髓瘤细胞系(RPMI 8226)与不同数量胞浆轻链阴性的白血病细胞系(KM-3)混合,发现DNA单项参数分析只能检出1:25KM-3稀释物中约4％的RPMI 8226非整倍体高峰,而采用DNA和Cyt Ig双重参数分析易检出<1％的RPMI 8226。并发现按计算预计的与双重参数分析所得到的骨髓瘤细胞百分数间存在密切相关。而用正常骨髓细胞替代KM-3与骨髓瘤细胞相混合得到的结果相同。2、检测骨髓瘤患者骨髓中微小残留病变;17例骨髓瘤患者骨髓中含有3～66％骨髓瘤细胞,运用双重参数分析法均能见到骨髓中骨髓瘤细胞。瘤细胞为超二倍体,
The authors used DNA and cytosolic immunoglobulins (CytIg) as cell clone markers to determine minimal residual myeloma cells in bone marrow and peripheral blood. Mixed with myeloma cell line (RPMI 8226) and different numbers of cytoplasmic light chain-negative leukemia cell line (KM-3) using artificial mixtures of multiple myeloma cell lines and found that DNA single parameter analysis can only detect 1: Approximately 4% of the RPMI 8226 aneuploidy peak in a 1: 25KM-3 dilution and <1% RPMI 8226 was easily detectable by DNA and Cyt Ig dual-parameter analysis. It was found that there was a close correlation between the predicted percentages of myeloma cells obtained from the double-parameter analysis. The same result was obtained by mixing normal myeloid cells with myeloma cells instead of KM-3. Detection of minimal residual disease in the bone marrow of patients with myeloma; 17 cases of myeloma patients with bone marrow contains 3 to 66% myeloma cells, using dual parameter analysis can see myeloma cells in the bone marrow. Tumor cells are diploid,